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Impaired therapeutic responses to anti-inflammatory glucocorticoids (GC) in chronic respiratory dis-
eases are partly attributable to interleukins and transforming growth factor b1 (TGF-b1). However,
previous efforts to prevent induction of GC insensitivity by targeting established canonical and
non-canonical TGF-b1 pathways have been unsuccessful. Here we elucidate a TGF-b1 signaling
pathway modulating GC activity that involves LIM domain kinase 2-mediated phosphorylation of co-
filin1. Severe, steroid-resistant asthmatic airway epithelium showed increased levels of immunoreac-
tive phospho-cofilin1. Phospho-cofilin1 was implicated in the activation of phospholipase D (PLD) to
generate the effector(s) (lyso)phosphatidic acid, which mimics the TGF-b1-induced GC insensitivity.
TGF-b1 induction of the nuclear hormone receptor corepressor, SMRT (NCOR2), was dependent on
cofilin1 and PLD activities. Depletion of SMRT prevented GC insensitivity. This pathway for GC insen-
sitivity offers several promising drug targets that potentially enable a safer approach to the modula-
tion of TGF-b1 in chronic inflammatory diseases than is afforded by global TGF-b1 inhibition.
INTRODUCTION
Glucocorticoids (GCs) are widely used in the treatment of inflammatory and autoimmune diseases, such as
asthma, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis (Rhen and Cidlowski,
2005). In most people with asthma, inflammation is well-controlled by inhaled GCs, whereas COPD-asso-
ciated inflammation shows limited responsiveness to GCs. Moreover, approximately 10% of asthmatic pa-
tients remain symptomatic while using high doses of GCs (Chung et al., 2014). The pharmacodynamicmani-
festation of GC insensitivity includes a rightward shift in the concentration-response curve or a depression
of the maximum response. Clinical GC insensitivity is defined as the presence of airway obstruction that is
not relieved after 2 weeks of oral GC treatment, representing a reduction in the maximum GC response
(Hew and Chung, 2010; Keenan et al., 2012).
GC activity in different cell types is dependent on the phenotype. Cell types not usually accorded a primary
role in response to GCs, including epithelium, smooth muscle, and fibroblast, have well-documented
capacity to add to the overall burden of inflammatory mediators (Keenan et al., 2012, 2015). Forming at
the interface between the host and the environment, airway epithelium detects environmental stimuli
and secretes a range of cytokines and chemokines that contribute to airway inflammation and airway struc-
tural changes in asthma (Lambrecht and Hammad, 2012) and are modulated by GC treatment. Thus the
airway or lung epithelium is the site of deposition and significant actions of inhaled GCs. A corollary of
the importance of the airway epithelium in asthma pathogenesis and GC activity is that in patients with
GC insensitivity this cell type also has the potential to contribute to clinical GC resistance.
GC anti-inflammatory activity can be impaired by pro-inflammatory cytokines, resulting in the insensitivity
to GCs in inflammatory diseases (Dejager et al., 2014). Inflammatory stimuli, including tumor necrosis factor
alpha, interleukin-1b (IL-1b), IL-17A, or viral infection, contribute to GC insensitivity in epithelium (Rider
et al., 2015; Webster Marketon and Corry, 2013; Zijlstra et al., 2012). However, the insensitivity induced
by transforming growth factor b1 (TGF-b1) demands most attention because of its extraordinary capacity
at picomolar concentrations to ablate GC anti-inflammatory activity in airway and lung epithelial cells
(Keenan et al., 2014; Salem et al., 2012). Moreover, we have recently identified that viral infection of human232 iScience 12, 232–246, February 22, 2019 ª 2019 The Authors.
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bronchial epithelial cells impairs GC anti-inflammatory activity through the induction of TGF-b1 activity (Xia
et al., 2017).
Increased activity of TGF-b1 in epithelium during the progression of inflammatory airway diseases is well
documented (Honkova et al., 2014; Torrego et al., 2007). TGF-b1 is established as a key driver of remodel-
ing in chronic respiratory diseases (Lachapelle et al., 2018). However, elevated levels of TGF-b1 in asthmatic
patients are not suppressed by the use of GCs (Chakir et al., 2003). Global inhibition of TGF-b1 results in
serious adverse effects including autoimmune colitis and cardiac valve defects (Anderton et al., 2011), pre-
cluding the acceptability of agents that inhibit receptor activation for non-oncological or life-threatening
indications (Lachapelle et al., 2018). We have previously excluded roles for Smad4-dependent nuclear
Smad signaling and the well-known non-canonical kinase pathways in the signaling of TGF-b1-induced
GC insensitivity (Keenan et al., 2014). Moreover, TGF-b1-induced impairment is not associated with
impaired GRa expression, nuclear location, or altered glucocorticoid receptor alpha (GRa) phosphoryla-
tion in BEAS-2B cell line (Keenan et al., 2014). Therefore a hitherto undescribed pathway mediating GC
insensitivity needs further investigation. The elucidation of this signaling operating in parallel to, but inde-
pendently of, established canonical and known non-canonical pathways offers the enticing prospect of se-
lective, clinically tractable approaches to TGF-b1 modulation.
Here, we show by unbiased transcriptomic RNA sequencing (RNA-seq) analyses that the GC insensitivity
induced by TGF-b1 is broad, rather than being restricted to genes regulated by transactivation. Moreover,
we identify phospho-cofilin1 as an essential link in the signaling chain subserving TGF-b1-induced GC
insensitivity using a combination of proteomic, pharmacological, and genetic approaches. The upstream
signaling revealed a LIMK2 pathway leading to the phosphorylation of cofilin1. PLD, a known downstream
effector of phospho-cofilin1 (Han et al., 2007), was implicated in the induction of the nuclear hormone core-
pressor, SMRT, the distal effector of GC insensitivity. We show here for the first time that the products of
PLD-mediated membrane phospholipid remodeling, lysophosphatidic acid (LPA) and phosphatidic acid
(PA), induce GC insensitivity.RESULTS
TGF-b1 Has Extensive Modulatory Influence on GC Activity
To investigate the global impact of TGF-b1 on GC gene regulation, we conducted RNA-seq analyses of
extracts of BEAS-2B cells (n = 3) incubated with TGF-b1 (40 pM), and then exposed to dexamethasone
(Dex, 30 nM), using concentrations previously established asmaximally effective (Keenan et al., 2014; Salem
et al., 2012; Xia et al., 2017). Genes influenced by TGF-b1 alone by more than 2-fold and those with smaller
but significant changes (applying a Benjamini and Hochberg [BH] false discovery rate [FDR] < 0.05) were
filtered from the analyzed set to avoid the confounding influence of direct TGF-b1 gene regulation. Based
on these criteria, 569 genes were differentially affected by Dex (BH FDR<0.05). Of the remaining 245 genes
suppressed by Dex, 181 were less suppressed in the presence of TGF-b1. Similarly, of the 324 genes
induced by Dex, 213 genes were induced to a lesser extent by the combination of TGF-b1 and Dex (Fig-
ure 1A). However, 40 genes downregulated by Dex showed greater downregulation following TGF-b1 con-
ditioning and 91 genes showed greater upregulation than induced by Dex alone (Figure 1A). Thus, TGF-b1
predominantly limited themagnitude of GC induction and repression of gene expression. The TGF-b1/Dex
interaction could be ascribed to a functional antagonism, whereby the effects of Dex are simply opposed
by the effects of TGF-b1 driving expression in the opposite direction, rather than being related to the
signal-transduction-based interaction that we propose. The exclusion of genes significantly affected by
TGF-b1 mitigates against, but does not preclude, this possibility. Thus we examined adding the TGF-b1
‘‘arithmetic effect’’ to the significant Dex effect and compared this result to the actual impact of prior
TGF-b1 conditioning on the subsequent Dex response for each of the 569 analyzed Dex changes in
gene expression. The absolute mean difference in the theoretically additive gene expression and the com-
bined gene expression effect is log2 0.55G 0.02 (p < 1015), indicating that the interaction is not explained
by any residual (non-significant) effects of TGF-b1 opposing those of Dex (Table S1). The molecular mech-
anism of GC-regulated gene expression is mainly through transactivation via binding to positive glucocor-
ticoid response element (pGRE) DNA-binding sequences and direct repression via binding to negative
GRE (nGRE) DNA-binding sequences and transrepression. We further analyzed whether the TGF-b1
impairment is confined to subsets of genes containing pGRE or nGRE or to those genes bearing
neither of the consensus GRE motifs in their promoter regions. We annotated our genes using DNA
sequences derived from the literature (Surjit et al., 2011). Although the nGRE-containing genes wereiScience 12, 232–246, February 22, 2019 233
Figure 1. TGF-b1 Extensively Impairs GC Activity
(A) Analysis of transcriptomes of BEAS-2B cells incubated with Dex with or without TGF-b1 conditioning. Cells were pre-
incubated with TGF-b1 (40 pM) for 24 h before stimulation with Dex (30 nM) or vehicle for 4 h. Data represent genes with a
false discovery rate (FDR) <0.05 and not differentially affected by TGF-b1 alone (1<log2 FC < 1 or FDR > 0.05). Numbers
of genes with specific patterns of GC-regulated expression are presented in the accompanying table together with
graphical symbols.
(B) Quantitative real-time PCR (qRT-PCR) analysis of selected GC-inducible genes.
(C) Effects of TGF-b1 on pro-inflammatory cytokine levels regulated by GC. A549 cells were incubated with TGF-b1
(40 pM) for 12 h and incubated with Dex (10 nM) 30 min before incubation with IL-1a (1 ng/mL) for another 16 h. Levels of
GM-CSF and IL-8 were measured by ELISA.
(D) Effects of TGF-b1 on the expression of GC-regulated proteins. BEAS-2B cells were incubated with TGF-b1 (40 pM) for
24 h and incubated with Dex (30 nM) for another 24 h.
Representative western blots are shown and aggregated data are presented as mean G SEM. (A) n = 3, (B) n = 5–6, (C)
n = 5, and (D) n = 6. N.D., not detectable. FC, fold control. Two-way ANOVA is used for (B); two-tailed Student’s t test is
used for (C, D). *p < 0.05, **p < 0.01, ***p < 0.001. (See also Tables S1, S2, and S3).under-represented in the set of genes that showed TGF-b1 impairment of Dex-induced gene expression,
the impairment effect is observed with genes that express nGRE, pGRE, both, or neither (Table S2). More-
over, ‘‘FunRich’’ gene set enrichment analyses suggested that TGF-b1-modulated Dex-influenced genes
across different biological pathways and processes (Table S3).
We investigated the underlying mechanism with a focus on the specific TGF-b1 impairment of GC-induced
genes documented as effectors of GC anti-inflammatory activity and regulation of cytokine production.234 iScience 12, 232–246, February 22, 2019
GC-induced mRNA encoding promyelocytic leukemia zinc finger (PLZF), FK506-binding protein 51
(FKBP5), and pyruvate dehydrogenase kinase 4 (PDK4) were suppressed by TGF-b1 (Figure 1B). GC induc-
tion of increased levels of the PLZF and FKBP5 proteins was also reduced by TGF-b1 (Figure 1D). TGF-b1
impairment of GC transrepressional mechanisms has been characterized in the A549 cell line (Salem et al.,
2012), so we used the A549 cell line to investigate TGF-b1 impairment of GC transrepression. TGF-b1 atten-
uated the maximum inhibitory effect of Dex on IL-1a-induced IL-8 and granulocyte-macrophage colony-
stimulating factor (GM-CSF) production in the A549 cell line (Figure 1C). The impact of these effects
can be appreciated when considering that the levels of GM-CSF increase approximately 10-fold from
12 G 5 pg/mL in the presence of IL1a/Dex to 106 G 24 pg/mL, in cells additionally conditioned by
TGF-b1. Thus our characterization indicates that TGF-b1 impairs GC-regulated gene expression changes
in airway epithelial cells via mechanisms that transcend discrete transcriptional influences of GC, such as
those dependent on nGRE, pGRE, or transcription factor repression.
Proteomic Analysis Reveals Phospho-cofilin1 as the Primary Candidate Mediator
in TGF-b1-Induced GC Insensitivity
We had excluded roles for Smad4 and a wide range of non-canonical kinase signaling pathways in the TGF-b1
modulation of steroid signaling, suggesting the involvement of a new pathway (Keenan et al., 2014). Candidate
signalingproteinswere assessedby anoperational proteomic approach affordedby2-dimensional differential in
gel electrophoresis (2D-DIGE). We prioritized candidate protein expression changes by exploiting an unex-
pected difference in the activity of the different TGF-b gene products, whereby both TGF-b1 and TGF-b3
impaired GRE activity, but TGF-b2 was inactive in both BEAS-2B and A549 cells (Figure S1A). The bioactivity of
TGF-b2 was validated not only by its induction of Smad7 (Figure S1B) but also by the induction of seven changes
in 2D-DIGE protein spots (Figure 2A). The 2D-DIGE experiment in BEAS-2B cells treated with each of TGF-b1–3
revealed that of the 748G 35 (n = 5) protein spots detected, three spots were differentially expressed in extracts
from TGF-b1- or TGF-b3-incubated cells, but not in those incubated with TGF-b2 (Figure 2A). Moreover, these
changes inproteinexpressionwere insensitive to inhibitionbya combinationofmitogen-activatedprotein kinase
(MAPK) and phosphatidylinositol 3-kinase (PI3K) pathway inhibitors that had been previously established to be
individually ineffective on the TGF-b1-induced GC insensitivity (Keenan et al., 2014; Salem et al., 2012) and are
now confirmed tobe ineffectivewhen used in combination (Figures S1C and S1D). These three spots were there-
fore prioritized for identification bypicking and then subjected to tryptic digest before analysis by liquid chroma-
tography-tandemmass spectrometry. The data were then analyzed byMascot to identify the candidate proteins
(listed in Table S4).
Phospho-cofilin1 was prioritized over the two other candidates because over-expression of cofilin1 had
been reported to inhibit GR activity (Ruegg et al., 2004), and the cofilin1 levels of lymphocytes from ste-
roid-insensitive asthmatic patients had been found to be inversely correlated with the ability of GC to sup-
press cytokine release (Vasavda et al., 2006). TGF-b1 and TGF-b3, but not TGF-b2, increased the phosphor-
ylation of cofilin1 through MAPK-independent pathways (Figures 2B and S1E). Moreover, the elevation of
phospho-cofilin1 levels by TGF-b1 was suppressed by 1 mM SB431542 (TbRI kinase inhibitor) (Figure S2A).
Upon TGF-b1 treatment, phospho-cofilin1 protein levels increased, whereas Smad3 levels decreased (Fig-
ure S2B), consistent with the suggestion that TGF-b1 increased phospho-cofilin1 levels via a Smad3-inde-
pendent, non-canonical kinase-dependent signaling pathway. However, further experiments are required
to make this conclusion, given that the Smad3-targeted small interfering RNA (siRNA) did not further
reduce the low Smad3 levels observed in the presence of TGF-b1 (Figure S2B). Incubation with cofilin1-tar-
geted siRNA, which reduced cofilin1 protein levels to less than 20%, markedly diminished the level of TGF-
b1-induced phospho-cofilin1 (Figure 2C). Cofilin1 siRNA completely prevented TGF-b1 inhibition of PLZF
and FKBP5 gene expression (Figure 2D). The percentage of TGF-b1 suppression of Dex-induced ENaCa
(epithelial sodium channel a) and PDK4 mRNA expression was reduced by cofilin1-targeting siRNA from
53%G 5% to 37%G 3% and from 54%G 8% to 38%G 5%, respectively. The relevance of phospho-cofilin1
was underlined by its elevated expression in the airway epithelium in biopsies from patients with severe,
steroid-resistant asthma (see Table S5 for demographic data) compared with non-asthmatic subjects or
those with mild-moderate asthma (Figure 2E).
TGF-b1-Induced Suppression of GC Activity Is due to the Activation of LIMK2
Cofilin1 phosphorylation is effected principally by the LIM domain kinase (LIMK). We therefore examined
the effect of the putative upstream kinase LIMK using the small-molecule inhibitor, LIMKi3 (Scott et al.,
2010). Cofilin1 phosphorylation was concentration-dependently reduced by LIMKi3 (1–10 mM). LIMKi3iScience 12, 232–246, February 22, 2019 235
Figure 2. Proteomic Analyses Prioritize Phospho-cofilin1 As a Mediator in TGF-b1-Induced GC Insensitivity
(A) The 2D-DIGE comparative analysis between control and TGF-b isoforms. BEAS-2B cells were incubated with TGF-b isoforms (40 pM each) for 24 h, and
lysates were subjected to 2D-DIGE. Overlay of Cy3 and Cy5 derived from a representative gel, highlighting differentially expressed protein spots: round for
up-regulation; square for down-regulation. CyDye minimal labeling as follows: Control-Cy5 versus TGF-b1-Cy3; Control-Cy3 versus TGF-b2-Cy5; Control-
Cy3 versus TGF-b3-Cy5. Venn diagram shows distribution of differentially expressed protein spots with TGF-b isoforms.
(B) Independent validation of TGF-b induction of phospho-cofilin1 by western blot.
(C) Western blot validation of successful knockdown of cofilin1 by cofilin1-targeted siRNA. (D) Effects of genetic ablation of cofilin1 on TGF-b1 impairment of
GC-inducible gene expression. BEAS-2B cells were transfected with negative control or cofilin1-targeted siRNA, incubated with TGF-b1 (40pM) for 24h, and
then incubated with Dex (30nM) for another 4h.
(E) Phospho-cofilin1 immunoreactivity in airway biopsies from subjects with increasing asthma severity scale bar, 30 mm.
Results are presented as mean G SEM or mean with interquartile range. (A) n = 3–5, (B) n = 5, (C and D) n = 4–5, (E) n = 7–10. ns, not significant. Two-way
ANOVA is used for (C, D); two-tailed paired Student’s t test is used for (A, B); non-parametric Kruskal-Wallis is used for (E). *p < 0.05, **p < 0.01, ***p < 0.001.
(See also Figures S1 and S2 and Table S4).(10 mM) completely prevented TGF-b1-induced elevation of phospho-cofilin1 levels (Figure 3A), but had no
effect on Plasminogen activator inhibitor-1 (PAI-1) mRNA expression (Figure 3B), a Smad3-and Smad4-
dependent TGF-b1 effect (Keenan et al., 2014). LIMKi3 prevented TGF-b1 suppression of GC induction
of GILZ, PLZF, FKBP5, and PDK4 gene expression (Figure 3B) and partially restored ENaCa gene expression
(Figure 3B) and GRE activity (Figures S3A and S3B). Reduction of LIMK2 expression by approximately 50%
using siRNA attenuated TGF-b1 impairment of GC-regulated PLZF and FKBP5 expression (Figure 3C),
whereas a 70% reduction of LIMK1 had no effect (Figure S3C). The differential influence of LIMK1 and236 iScience 12, 232–246, February 22, 2019
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Figure 3. TGF-b1-Induced Impairment of GC Activity Is Dependent on LIM Kinase 2 Activity
(A) Pharmacological inhibition of LIMK inhibits TGF-b1-induced increase in phosho-cofilin1 levels. BEAS-2B cells were incubated with LIMKi3 (1–10 mM) for
30 min before incubation with TGF-b1 (40 pM) for 24 h.
(B) Smad-dependent PAI-1 and GC-inducible gene expression targets were determined by qRT-PCR in BEAS-2B cells incubated with LIMKi3 (10 mM) for
30 min before TGF-b1 (40 pM) for 24 h followed by incubation with Dex (30 nM) for 4 h.
(C) BEAS-2B cells transfected with negative control or LIMK2-targeted siRNA were incubated with TGF-b1 (40 pM) for 24 h, followed by incubation with Dex
(30 nM) for 4 h before mRNA measurement.
(D) Levels of GM-CSF and IL-8 were measured by ELISA and expressed as a percentage of the IL-1a response. A549 cells were incubated with LIMKi3 (10 mM)
for 30 min before TGF-b1 (40 pM) for 12 h and incubated with Dex (10 nM) 30 min before incubation with IL-1a (1 ng/mL) for another 16 h.
(E) Effects of pharmacological inhibition of LIMK on TGF-b1 impairment of GC activity in human bronchial epithelial cells differentiated for 28 days at air-
liquid interface (ALI). Cells were incubated with LIMKi3 (10 mM) 30 min before incubation with TGF-b1 (40 pM) for 24 h, then incubated with Dex (100 nM) or
vehicle control for 4 h.
Data are presented as mean G SEM from n = 4 individual donors. (A–D) n = 5–6 (E) = 4. ns, not significant. Two-way ANOVA is used for (A–D); two-tailed
paired Student’s t test is used for (E). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (See also Figure S3).LIMK2 on the TGF-b1-impairedGC activity is consistent with accumulating evidence demonstrating the po-
tential association of LIMK2 level, but not LIMK1, with asthma severity in inflammatory cells (Aoki et al.,
2009; Bigler et al., 2017; Persson et al., 2015).
In A549 cells, IL-1a-induced elevation of GM-CSF level was completely prevented by Dex. TGF-b1
enhanced IL-1a-induced increases in GM-CSF levels and compromised the Dex suppression of GM-CSF
levels. Inhibition of LIMK using LIMKi3 (10 mM) restored much of the activity of Dex in suppressing both
GM-CSF and IL-8 levels (Figure 3D).
We have previously established the TGF-b1 modulation of GC in air-liquid interface (ALI) differentiated
primary human epithelial organotypic cultures (Keenan et al., 2014). This organotypic culture setting
engenders a differentiated cell population expressing functional activity, such as beating cilia and mucous
production, and an intact epithelial barrier. In ALI cultures, TGF-b1 inhibition of Dex-induced GILZ and
ENaCa expression was prevented by the inhibition of LIMK (Figure 3E).
There is a well-established connection between the TGF-b1 receptor and RhoA/B and GTP-bound Cdc42
activation (Kardassis et al., 2009). Moreover, LIMK activation is widely thought to result from phosphoryla-
tion by ROCK or Cdc42/PAK (Lee-Hoeflich et al., 2004; Sumi et al., 2000). These TGF-b1-activated pathways
have been documented in a signaling chain in Swiss 3T3 fibroblasts (Vardouli et al., 2005), but are not yet
evidenced in an epithelial cell phenotype. Hence, we investigated the effects of blocking ROCK (10 mM
Y27632), Cdc42 (5 mMML141), or both using well-validated inhibitors at concentrations that have been pre-
viously reported by other groups to effectively inhibit the respective enzymatic activities (Hong et al., 2013;
Sumi et al., 2000). Neither the ROCK inhibitor or the Cdc42 inhibitor alone nor their combination was able
to even partially mimic the effect of inhibiting LIMK (Figures 4A and S4A).
Cofilin1 phosphorylation at serine 3 by LIM domain kinase switches off the actin filament severing activity of
cofilin1 (Vardouli et al., 2005). However, neither LIMKi3 (10 mM) nor the inhibitor of Cdc42 ML141 (5 mM)
affected the TGF-b1-induced re-distribution of actin between F and G forms. The ROCK inhibitor
Y27632 (10 mM) prevented TGF-b1-induced increases in F-actin levels (Figure 4B), as did the F-actin-dis-
rupting agent, cytochalasin B (Figure S4B), but neither Y27632 nor cytochalasin B restored GC-inducible
gene expression (Figures 4A and S4C). These findings dissociate actin cytoskeletal changes induced by
TGF-b1 from impaired GC responses.TGF-b1 Impairment of GC Activity Is due to Phospho-cofilin1-Dependent Phospholipase
D Activation
Although cofilin1 is widely regarded as the active form of the protein, phospho-cofilin1 has also been re-
ported to activate phospholipase D1 (PLD1) (Han et al., 2007). We therefore examined the possible involve-
ment of PLD in TGF-b1 signaling of GC insensitivity, using the selective inhibitors VU01550699 (7.5 mM) or
FIPI (10 mM), at concentrations based on previous studies (Kang et al., 2013; Su et al., 2009) and as further
validated in our initial experiments. Incubation of BEAS-2B cells with VU01550699 (7.5 mM) prevented TGF-
b1 suppression of Dex-induced expression of GILZ, ENaCa, and FKBP5 and substantially enhanced Dex-
induced GILZ mRNA expression (Figure 5A). Use of FIPI (10 mM) further confirmed the involvement
of the PLD in TGF-b1 suppression of GC-regulated gene expression (Figure 5B). Moreover, both238 iScience 12, 232–246, February 22, 2019
Figure 4. TGF-b1-Induced Impairment of GC Activity Is Not Due to the Activity of ROCK/Cdc42 or TGF-b1-
Induced Actin Reorganization
(A) BEAS-2B cells were incubated with the ROCK inhibitor Y27632 (10 mM) or the Cdc42 inhibitor ML141 (5 mM) for 30 min
before TGF-b1 (40 pM, 24 h incubation) followed by Dex (30 nM) incubation for 4 h before mRNA measurement.
(B) Fluorescence imaging of F-actin (green) and G-actin (red) in BEAS-2B cells incubated with LIMKi3 (10 mM), Y27632
(10 mM), and ML141 (5 mM) 30 min before TGF-b1 (40 pM) for 24 h; scale bar, 50 mm.
Data are presented as meanG SEM. (A) n = 3–6, (B) n = 3–6. Two-way ANOVA is used throughout. *p < 0.05, **p < 0.01,
***p < 0.001. ns, not significant. (See also Figure S4).VU01550699 and FIPI reduced TGF-b1 impairment of Dex-induced GRE activity (Figure S5A). PLD was
further implicated by the restoration of GC responsiveness through the use of PLD1/2-targeted siRNA,
with combined knockdown of PLD1 and PLD2 attenuating the TGF-b1 inhibition of Dex-induced FKBP5
and PLZF mRNA expression (Figure 5C). Individual PLD1 and PLD2 knockdown each attenuated the inhib-
itory effects of TGF-b1 on GILZ and PLZF mRNA expression (Figure S5B). The TGF-b1 impairment of Dex
suppression of pro-inflammatory cytokines GM-CSF and IL-8 levels was prevented by the inhibition of
PLD by VU01550699 (7.5 mM) (Figure 5D), as was the TGF-b1-induced inhibition of GILZ and ENaCa expres-
sion in the ALI cultures (Figure 5E). These data strongly supported a role for PLD in the signaling down-
stream of phospho-cofilin1 to mediate TGF-b1 impairment of GC activity.
Activation of PLD increases the hydrolysis of phosphatidylcholine (PC) to choline and the second
messenger lipid PA, which may be further metabolized to LPA and diacylglycerol (Csaki et al., 2013). Exog-
enous PLD products, PA and LPA, mimicked the effect of TGF-b1 in repressing the Dex-induced GRE
activity (Figure S5C) and in decreasing GRE-regulated genes (Figures 5F and 5G), without cytotoxicity
(Figure S5D). The mimicry of TGF-b1 by exogenous (lyso)phosphatidic acid could suggest that these PC
metabolites were being mobilized as autocrine mediators of TGF-b1. This possibility was examined by
the transfer of TGF-b1-conditioned supernatant to TGF-b1-naive BEAS-2B cells. BEAS-2B cells were incu-
bated with TGF-b1 (40 pM) for 6 or 24 h to generate conditioned medium. Before transfer to serum-starved
BEAS-2B cells, the ALK5 inhibitor SB431542 (10 mM) was added to the medium to block ALK5 signaling
induced by the transferred TGF-b1. The conditioned medium did not contain a transferable GC suppres-
sive factor (Figures S6A and S6B), leading us to conclude that the (lyso)phosphatidic acid induced by TGF-
b1 acts within the intracellular compartment. Phospholipid remodeling could allow LPA access to LPA re-
ceptors, whereas blockade of LPA receptors (1–3) using Ki16425 (10 mM) (Ohta et al., 2003) had no effect on
the impairment of GC-induced gene expression caused by either TGF-b1 or (lyso)phosphatidic acid
(Figure S6C).iScience 12, 232–246, February 22, 2019 239
Figure 5. Inhibition of Phospholipase D (PLD) Prevents TGF-b1 Induction of GC Insensitivity
(A and B) Effects of PLD inhibitors (A) VU0155069 (VU01, 7.5 mM) or (B) FIPI (10 mM) on TGF-b1-induced suppression of GC-inducible gene expression was
investigated.
(C) Effects of genetic depletion of PLD1/2 on TGF-b1-suppressed GC activity was investigated by qRT-PCR.
(D) Levels of GM-CSF and IL-8 were measured by ELISA and expressed as a percentage of the IL-1a response. A549 cells were incubated with VU0155069
(7.5 mM) for 30 min before TGF-b1 (40 pM) for 12 h and incubated with Dex (10 nM) 30 min before incubation with IL-1a (1 ng/mL) for another 16 h.
(E) Effects of pharmacological inhibition of PLD on TGF-b1 impairment of GC activity in human bronchial epithelial cells differentiated for 28 days at air-liquid
interface (ALI).
(F andG) Effects of exogenous PA and LPA on Dex-inducible gene expression. BEAS-2B cells were exposed to (F) PA (10 or 30 mg/mL) or (G) LPA (10 or 30 mM)
for 24 h, before incubation with Dex (30 nM) for 4 h.
Data are presented as meanG SEM. (A–D) n = 4–5, (E–G) n = 4. ns, not significant. Two-way ANOVA is used for (A–D; F–G); two-tailed paired Student’s t test
is used for (E). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (See also Figure S5).SMRT Induction Downstream of Phospho-cofilin1/PLD Mediates TGF-b1-Induced Repression
of GR Target Gene Expression
The repressive activities of TGF-b1 and PA on peroxisome proliferator-activated receptor (PPAR) have been
previously ascribed to stabilization of the PPAR interaction with the corepressor SMRT in macrophages and
fibroblasts (Stockert et al., 2011; Tsukahara et al., 2010). We therefore analyzed whether TGF-b1 influences
SMRT in BEAS-2B cells. TGF-b1 significantly increased SMRT levels, an effect that was dependent on the240 iScience 12, 232–246, February 22, 2019
Figure 6. SMRT Induction Downstream of Phospho-cofilin1/PLD Activity Plays a Role in the TGF-b1-Induced Repression of GR Target Genes
(A and B) Effects of genetic deletion of (A) cofilin1 and (B) PLD1/2 on SMRT expression. Cell lysates were the same as those used in Figures 2D and 5C.
(C) Validation of successful knockdown of SMRT-targeted siRNA in BEAS-2B cells. (D) Effects of genetic ablation of SMRT on GC-inducible gene expression.
BEAS-2B cells transfected with negative control or SMRT-targeted siRNA, were incubated with TGF-b1 (40pM) for 24h, and then incubated with Dex (30nM)
for another 4h before mRNA measurement.
Data are presented as mean G SEM. (A–D) n = 5. ns, not significant. Two-way ANOVA is used for (A–D). *p < 0.05, **p < 0.01, ***p < 0.001.
(See also Figure S7).action of cofilin1 and PLD (Figures 6A and 6B). SMRT-targeted siRNA prevented the TGF-b1 induction of
SMRT protein levels (Figure 6C), preventing TGF-b1 suppression of PLZF and FKBP5 mRNA, and attenu-
ating suppression of ENaCa (percentage inhibition reduced from 67%G 4% to 50%G 5%) and PDK4 (per-
centage inhibition reduced from 65%G 3% to 47%G 4%) mRNA expression, respectively (Figures 6D, S7A,
and S7B). Moreover, TGF-b1, PA, and LPA each completely prevented the transcriptional regulation of
CYP27A1 (encoding cytochrome P450 family 27 subfamily Amember 1) by the PPARg agonist, rosiglitazone
(Figure S8), consistent with a role for intracellular PA in mediating TGF-b1 inhibition of the nuclear hormone
receptors, GR and PPARg.
DISCUSSION
We identified a broadmodulatory impact of TGF-b1 onGC activity, showing reducedmaximal responses of
both GC-induced and GC-repressed genes. A TGF-b1 signaling pathway was elucidated comprising
LIMK2-mediated phosphorylation of cofilin1 that requires PLD1 and PLD2 enzyme activity and induction
of the nuclear hormone corepressor SMRT (Figure 7). The increased expression of phospho-cofilin1 in
the airway epithelium of severe, steroid-resistant asthmatic patients further supported the relevance of
our findings, which we believe will facilitate drug discovery efforts focused on safely blocking the contribu-
tion of TGF-b1 to chronic inflammatory diseases (Lachapelle et al., 2018).
The relative importance of transactivation and transrepression to the anti-inflammatory activity of GC re-
mains controversial (Keenan et al., 2015). GR dimer-dependent transactivation is increasingly regarded
as essential for certain of the anti-inflammatory activities of GR (Vandevyver et al., 2013). As TGF-b1 sup-
pressed GC-sensitive genes associated with pGRE, nGRE, transrepression, or other mechanisms of regu-
lation with similar frequencies, the exogenous TGF-b1 effect is not limited in scope to a specific GC gene
regulatory mechanism. We selected a panel of GRE-dependent GC-responsive genes, including GILZ,
ENaCa, PLZF, PDK4, FKBP5, as well as the cytokines, GM-CSF and IL-8, to assess the impact of TGF-b1
on GC sensitivity. This selection was based on their importance in inflammation, as described briefly below,iScience 12, 232–246, February 22, 2019 241
Figure 7. LIMK2-Mediated Cofilin1 Phosphorylation Signals TGF-b1-Induced GC Insensitivity
Phospho-cofilin1 is implicated as a key link in the chain of signalling behavior of TGF-b1-induced GC insensitivity. The
activation of LIMK2 appears to be independent of known upstream regulators ROCK or Cdc42. Phospho-cofilin1-
activated PLD mediates SMRT induction, which limits GR target gene regulation. The interventions including small-
molecule inhibitors and siRNA are summarized in boxes.and having comparative data from prior studies (Keenan et al., 2014; Salem et al., 2012; Xia et al., 2017).
GILZ mediates some of the anti-inflammatory effects of Dex in epithelial cells (Eddleston et al., 2007).
Impaired epithelium sodium channel expression results in excess fluid and pulmonary edema (Kerem
et al., 1999). FKBP5 is not only a biomarker of GC responsiveness but also is implicated in modulating
the nuclear translocation and transcriptional activity of nuclear factor-kB (Erlejman et al., 2014). PLZF is a
GC-inducible transcription factor that arrests cell cycle by inducing the expression of CDK inhibitors (Naito
et al., 2015). PDK4 inactivates the pyruvate dehydrogenase complex (PDC), which catalyzes the conversion
of pyruvate to acetyl-CoA. PDC metabolite flux is involved in the immunometabolic reprogramming
of macrophages, a process that allows cellular defense mechanisms to accommodate the different micro-
environments encountered in inflamed tissues (O’Neill and Pearce, 2016). Imparied GC induction of GILZ,
ENaCa, FKBP5, PLZF, and PDK4 could amplify inflammation in the airway wall in asthma.
TGF-b1 impaired GC regulatory effects on the pro-inflammatory cytokines, IL-8 and GM-CSF. IL-8, a power-
ful chemoattractant and activator of neutrophils, is detected at increased levels in severe asthma (Shannon
et al., 2008). Neutrophils are generally considered to be less directly sensitive to GC treatment. In GC-resis-
tant asthma, inhibition of IL-8 release by GC is impaired (Nair et al., 2015; Wang et al., 2016). GM-CSF
facilitates robust eosinophilic inflammation, long-lasting antigen-specific Th2 inflammation, mucous pro-
duction, and airway hyperresponsiveness (Llop-Guevara et al., 2014). The compromised GC regulation
of these inflammogens in epithelia conditioned by TGF-b1 is likely to contribute to the severity and limit
the therapeutic responsiveness of chronic inflammation to GCs.
Global inhibition of TGF-b1 or ALK5 activity is known to increase the risk of autoimmune disorders and heart
valve lesions (Anderton et al., 2011). Therefore further understanding of the TGF-b1 signaling cascades that242 iScience 12, 232–246, February 22, 2019
interfere with GC activity may identify targets downstream of the receptors for selective restoration of GC
responses, which avoid the detrimental effect of global TGF-b1 inhibition (Lachapelle et al., 2018). We used a
hypothesis-free proteomic approach to examine the signaling of GC resistance by TGF-b1 because hypothe-
sis-driven approaches, including the use of a wide panel of kinase inhibitors and effective Smad4 inhibition
(Keenan et al., 2014; Salemet al., 2012), had been exhaustedwithout success. Three candidate signalingproteins
were prioritized by (1) inclusion of protein changes common to the active TGF-b forms, TGF-b1 and TGF-b3; (2)
exclusion of changes inducedby TGF-b2, whichdid not induceGC impairment; and (3) exclusion of changes that
were prevented by the combination of MAPK and PI3K-targeting small-molecule inhibitors that failed to block
TGF-b1 impairment of GC responses. Phospho-cofilin1 was further prioritized based on studies implicating
cofilin1 in steroid sensitivity (Ruegg et al., 2004; Vasavda et al., 2006).
As one of the main activities of cofilin1 is actin severing, our attention turned to the possibility that TGF-b1
impairment of GC activity could be secondary to changes in the actin cytoskeleton, and possibly to influ-
ences on cellular mechanics (Krishnan et al., 2016). However, pharmacological inhibitors of LIMK and
ROCK/Cdc42 showed differential effects on TGF-b1-induced phosphorylated-cofilin1, GC insensitivity,
and actin polymerization. The ROCK inhibitor and cytochalasin B prevented TGF-b1 induction of F-actin
levels without restoring GC activity, whereas the LIMK inhibitor prevented cofilin1 phosphorylation and
restored GC activity, without effect on TGF-b1-induced F-actin. These observations do not support a
role for actin cytoskeletal assembly in the regulation of GC sensitivity.
Although phospho-cofilin1 had been widely considered to be inactive, it was subsequently convincingly
demonstrated to be an activator of PLD1 (Han et al., 2007, 2011). Aberrant PLD activity has been identified
in chronic inflammatory autoimmune disorders and in allergic asthma (Choi et al., 2015; Kang et al., 2013).
Moreover, TGF-b1 increases PLD activity and increases the levels of PA and PA-related metabolites in
epithelial cell lines (Zhou et al., 2000). We sought to establish whether there is a link between PLD and
the TGF-b1 suppression of GC activity. TGF-b1 suppression of GC activity in epithelial cells was prevented
by reducing the activity of PLD, consistent with a pivotal role for phospho-cofilin1-activated PLD in TGF-b1
impairment of GC activity (Figure 7). Importantly, exogenous PA and LPA mimicked the effects of TGF-b1
on a panel of Dex-inducible genes and GRE activity. This observation linking PA or LPA and GC sensitivity
has implications beyond TGF-b1 to a broader relationship between PLD products and GC sensitivity. The
levels of polyunsaturated LPA in human bronchoalveolar lavage (BAL) fluid increase 3-fold after segmental
allergen challenge (to1.5 mM) (Georas et al., 2007). When accounting for 100-fold dilution of airway sur-
face fluid by the instilled lavage fluid, the epithelium may be exposed to LPA in situ of over 100 mM, which
exceeds the concentrations of exogenous LPA and PA required tomimic GC resistance. LPA present in bio-
logical fluids, such as plasma and BAL, is thought to initiate effects in airway inflammation and remodeling
by activation of cell surface G-protein coupled LPA1–7 receptors (Zhao and Natarajan, 2013), leading to the
question of whether TGF-b1 mobilized LPA to exert intra- or extracellular effects. However, a series of care-
ful supernatant transfer experiments indicated that the TGF-b1 impairment of GC activity was not accom-
panied by the release of transferable activity in the conditioned medium. Moreover, blockade of LPA re-
ceptors had no effect on the impairment of GC activity caused by either TGF-b1 or exogenous PA or
LPA. Therefore extracellular activation of LPA receptors is less likely to account for the TGF-b1 effect
than intracellular mobilization and action of PLD products.
Both PA and LPA are reported to bind to certain nuclear hormone receptors, including PPARg (McIntyre
et al., 2003). PA has been shown to inhibit PPARg transactivation with high potency and high specificity,
by stabilizing the interaction of PPARg with the corepressor SMRT (Tsukahara et al., 2010). Moreover, PA
has a biphasic influence on epidermal growth factor receptor (EGFR) expression, whereby lower concen-
trations of PA enable and higher concentrations impede PPARa/LXRa binding to the EGFR promoter (Hen-
kels et al., 2016). We have now shown that the corepressor SMRT is a transcriptional target of TGF-b1
through a chain of signaling linking CK1d/ 3to phospho-cofilin1-activated PLD. The siRNA-mediated inhi-
bition of SMRT leads to a strong derepression of TGF-b1-targeted GR gene expression, suggesting that
SMRT signals GC resistance downstream of the activated PLD.
In summary, we establish that TGF-b1 potently induces insensitivity to GC activity. Pharmacological and
genetic approaches implicated a chain of signaling through LIMK2/phospho-cofilin1/PLD, liberating PA
and LPA to induce GC insensitivity through the induction of SMRT. Our findings identify new drug targets
to modulate TGF-b1 that may be amenable to safe modulation by avoiding interference in essential growthiScience 12, 232–246, February 22, 2019 243
and immunoregulatory TGF-b1 activities that are mediated by canonical and well-established non-canon-
ical pathways operating upstream or independently of this pathway.
Limitations of the Study
We have provided compelling evidence that SMRT links TGF-b1 and GC activity, acting through a chain of
signaling involving LIMK2 to phospho-cofilin1-activated PLD to induce GC insensitivity. However, the
detailed mechanism underlying ALK5-mediated increases in the level of phospho-cofilin1 and PLD-medi-
ated increases in the level of SMRT remain unsolved.We aim to address the translational significance of our
findings in future studies designed to better understand the physiological functions of the identified novel
non-canonical TGF-b1 signaling pathway in steroid-resistant airway diseases.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file
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Figure S1. Strategies for narrowing the candidate pool, related to Figure 2.  (A) Effects of TGF-b1-
3 on Dex-induced GRE activity in BEAS-2B and A549 cells transiently transfected with GRE-SEAP 
reporter constructs and incubated with TGF-b1, TGF-b2 or TGF-b3 (40pM each). (B) Serum-starved 
BEAS-2B cells were incubated with TGF-b1, TGF-b2 or TGF-b3 (40pM each) for 28h before mRNA 
measurement. (C) BEAS-2B cells transiently transfected with GRE-SEAP reporter construct were 
incubated with the combination of inhibitors of p38MAPK (1µM SB202190), ERK1/2 (1µM U0126), JNK 
(1µM SP600125), PI3K (10µM LY294002) for 30 min prior and during exposure to TGF-b1 (40pM) for 
24h, followed by Dex (30nM) for another 24h. (D) The 2D-DIGE comparative analysis between control 
and TGF-b1 in the presence of multiple kinase inhibitors. Inhibitors (Inhb.)-Cy5 vs Inhibitors + TGF-
b1-Cy3. (E) Representative western blot showing the kinase inhibitor combination does not prevent 
TGF-b1 increases in phospho-cofilin1 levels as confirmed by analysis of data presented as mean ± SEM. 
(A, B, E) n=5. (C, D) n=3. Two-way ANOVA is used for (A, C, E). two-tailed paired Student’s t test 
applied for (B, D). *p<0.05, **p<0.01, ***p<0.001. ns, not significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. TGF-b1-induced phospho-cofilin1 is dependent on ALK5, but not Smad3 activity, 
related to Figure 2. (A) BEAS-2B cells were pre-incubated with SB431542 (1µM) for 30min prior to 
incubation with TGF-b1 (40pM) for 24h. (B) BEAS-2B cells transiently transfected with Smad3-targeted 
siRNA were incubated with TGF-b1 (40pM) for 24h. The representative blot and quantification are 
shown here. Results are presented as mean ± SEM for n=3-4. Two-way ANOVA and two-tailed paired 
Student’s t test are used. *p<0.05, **p<0.01, ###p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. Pharmacological inhibition of LIMK attenuates TGF-b1 suppression of GRE activity, 
related to Figure 3.  (A, B) BEAS-2B cells transiently transfected with GRE-SEAP reporter constructs 
were incubated with LIMKi3 (10µM) 30min prior to TGF-b1 (40pM) for 24h, then stimulated with Dex 
(30nM) for another 24h. (C) BEAS-2B cells transfected with negative control, LIMK1-targeted siRNA, 
were incubated with TGF-b1 (40pM) for 24h, followed by incubation with Dex (30nM) for 4h for mRNA 
measurement. Results are presented as mean ± SEM. (A, B, C) n=5. Two-way ANOVA is used for (A, 
C); two-tailed Student’s t test is used for (A, B). *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Pharmacological inhibition of ROCK/Cdc42 does not prevent TGF-b1-induced 
phospho-cofilin1; TGF-b1-induced actin reorganization does not affect TGF-b1 repression of GC 
target gene expression, related to Figure 4.  (A)  Serum-starved BEAS-2B cells were pre-incubated with 
either ROCK inhibitor (Y27632, 10μM), or Cdc42 inhibitor (ML141, 5μM), or combined inhibitors 
(10μM Y27632 and 5μM ML141), 30 minutes prior to TGF-b1 (40pM) for 24 hours. Cell lysate were 
collected and subjected to western blotting. Result is presented as mean ±	  SEM for n=4 independent 
experiments. (B, C) F-G actin staining for BEAS-2B cells incubated cytochalasin B (0.5µg/ml) with 
30min prior to TGF-b1 (40pM) for 24h. scale bar=50µm. Effects of cytochalasin B (0.5µg/ml) on TGF-
b1 impairment of GC-inducible gene expression. Two-way ANOVA is used. *p<0.05, **p<0.01, 
***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 Figure S5. Inhibition of PLD attenuates TGF-b1 suppression of GC activity, and exogenous PLD 
products mimic TGF-b1 effects, related to Figure 5. (A) BEAS-2B cells transiently transfected with 
GRE-SEAP reporter constructs were incubated with either VU0155069 (5µM) or FIPI (10µM) 30min 
prior to TGF-b1 (40pM) for 24h, then incubated with Dex (30nM) for another 24h for GRE-SEAP 
measurement. (B) Effects of individual PLD1 or PLD2 siRNA on PLD1 and PLD2 mRNA expression, 
respectively, and on TGF-b1 suppression of Dex-inducible gene expression in BEAS-2B cells. (C) 
BEAS-2B cells transiently transfected with GRE-SEAP reporter constructs were incubated with either 
PA (1-30µg/ml) or LPA (1-30µM) 30min prior incubation with Dex (30nM) for another 24h for GRE-
SEAP measurement. (D) Experiments of the same duration as in (C) were undertaken to ascertain the 
cytotoxicity, if any, of PA or LPA by measuring viable cell numbers at the end of the incubation period.  
Data are presented as mean ± SEM. (A-D) n=4-5. Two-way ANOVA and two-tailed Student’s t test are 
used. *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. TGF-b1 suppression of GC activity is not due to an extracellular product, related to 
figure 5. (A, B) BEAS-2B cell were incubated with vehicle or TGF-b1 (40pM) for 6h (A) or 24h (B) to 
generate conditioned medium. Vehicle or SB431542 (10µM) was added to conditioned medium prior to 
its addition to serum-starved BEAS-2B cells. Cells were incubated directly with TGF-b1 (40pM) or pre-
treated with conditioned medium for another 24h, then incubated with Dex (30nM) for 4h before mRNA 
measurement. (C) Blockade of LPA receptor does not influence the impairment of GC inducible gene 
expression. BEAS-2B cells were incubated with Ki16425 (10µM) 30min prior to TGF-b1 (40pM), or 
PA (30µg/ml), or LPA (30µM) for 24h, prior to the stimulation with Dex (30nM) for 4h. Data are 
presented as mean ± SEM. (A) n=4, (B) n=5, (C) 3-4. CM, conditioned medium. Two-way ANOVA is 
used for (A, B, C). ns, not significant. *p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7. Genetic deletion of SMRT attenuates TGF-b1-induced repression of GR target genes, 
related to figure 6.  (A, B) BEAS-2B cells transfected with negative control siRNA, SMRT-targeted 
siRNA, were incubated with TGF-b1 (40pM) for 24h, then incubated with Dex (30nM) for another 4h 
before mRNA measurement. Data are presented as mean±SEM. (A, B) n=4. ns, not significant. Two-
way ANOVA and two-tailed Student’s t test are used. *p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S8. PPARg-targeted gene is inhibited by TGF-b1, PA and LPA, related to figure 6. Serum 
starved BEAS-2B cells were treated with either TGF-b1 (40pM), or PA (30μg/ml), or LPA (30μM) for 
24h, and then stimulated with rosiglitazone (ROSI, 10μM) for a further 4h, after which RNA was 
extracted and analysed by qRT-PCR. Results are presented as mean ±	  SEM. n=4. Two-way ANOVA is 
used. *p<0.05, **p<0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2. Classification of specific TGF-b1-impaired Dex-responsive genes based on the 
distribution of pGRE and nGRE, related to Figure 1.  
 
   nGRE pGRE Both None Total 
Dex up-
regulated 
genes  
Unimpaired TGF-b1+Dex>Dex 0 35 3 53 91 
impaired TGF-b1+Dex<Dex 11 75 7 120 213 
 
Dex down-
regulated 
genes 
Unimpaired TGF-b1+Dex<Dex  1 12 0 27 40 
impaired TGF-b1+Dex>Dex  9 55 5 112 181 
 
Fisher’s exact test comparing the number of Dex up-regulated genes impaired by TGF-b1 (TGF-
b1+Dex<Dex), comparing those genes bearing an nGRE and those bearing a  pGRE in the promoter, 
p=0.03 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4. List of differentially expressed proteins identified by mass spectrometry, related to 
Figure 2. 
  
Master# Protein ID t-test Ave 
Ratio 
Protein 
Score 
PI 
1 361   Tropomyosin 1 
(Alpha) isoform 1 
0.037 2.01 787 4.69 
2 478 Phosphoglycerate mutase 1 0.070 1.89 148 6.67 
3 525 Triosephosphate isomerase 0.050 1.44 931 6.45 
4 537 Proteasome subunit alpha type 0.049 -1.42 184 8.59 
5 715 Cofilin-1 (p) 0.014 1.78 435 8.51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S5. Demographic data for subjects from the MESCA cohort from whom biopsies were 
obtained for immunohistochemistry, related to Figure 2. 
 Non-Asthma Mild Asthma# Moderate Asthma# Severe Asthma# 
Subject n (M/F)  10 (6/4) 10 (6/4) 7 (7/0) 9 (2/7) 
FEV1 % predict 108 (98-115) 103 (94-107) 60 (57-65) 64 (58-80) 
Atopic (%) 50 90 100 56 
Current smokers (%) 50 30 14 0 
      Current treatment (%)  
b2-adrenoceptor 
agonists 
0 90 100 100 
Inhaled steroids 0 80 100 100 
Oral steroids 0 20 14 100 
 
Data presented as median (interquartile range) or %. M: male; F: female; FEV1: forced expiratory volume 
in one second; % pred: % predicted. #: classified using Global Initiative for Asthma guidelines.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transparent Methods 
 
Cell culture and reagents. BEAS-2B bronchial and A549 lung adenocarcinoma epithelial cells were 
cultured as described previously (Salem et al., 2012). Primary HBECs were purchased from Lonza and 
cultured using B-ALITM BulletKitTM (Lonza) according to manufacturer’s instructions. Primary HBECs 
were seeded and differentiated for 28 days at air-liquid interface on fibrillar collagen (30µg/ml)-coated 
24-well Corning® Transwell® inserts (0.4µm) (Sigma-Aldrich, CLS3470-48EA). Cell differentiation was 
confirmed by the measurement of trans-epithelial electrical resistance (TEER) using an EVOM2 
Voltammeter (WPI, Sarasota, FL) and visualization of beating cilia. 
 
Main reagents used in this study are as follow: Recombinant human TGF-b1 protein (R&D 
systems, 240-B-002); Recombinant human TGF-b2 protein (Sino Biological Inc., 10382-H08H); 
Recombinant human TGF-b3 protein (PeproTech, AF-100-36E); Dexamethasone (Sigma-Aldrich, 
D1756); SB202190 (CalBiochem, 559388); U0126 (Merck Millipore, 662005); SP600125 (Merck 
Millipore, 420119); LY294002 (Merck Millipore, 440202); LIMKi3 (Merck Millipore, 435930); 
Y27632 (TOCRIS, 1254); ML141 (TOCRIS, 4266); Cytochalasin B (Sigma-Aldrich, C6762); 
VU0155069 (Santa Cruz Biotechnology, sc-224371A); FIPI (Santa Cruz Biotechnology, sc-294594); PA 
(Sigma, P9511); LPA (Sigma, L7260); SB431542 (Sigma, S4317); Ki16425 (Cayman, 10012659). 
 
Transcriptomic analysis. Biological replicates (n=3) of samples underwent RNA-seq was performed in 
the Melbourne Translational Genomic Platform, University of Melbourne. All clean reads were mapped 
to the human reference genome GRCh38-hg38 assembly using Rsubread package. Read alignment was 
conducted using featureCount and gene expression values were calculated for each gene as counts per 
million (cpm). Relative transcript abundances and differentially expressed genes were then determined 
using the edgeR package. Genes with less than 1 cpm in at least three samples were filtered out from 
further analyses, the remaining gene expression levels were then subjected to pairwise comparisons to 
identify differentially expressed genes applying a “Benjamini and Hochberg” multiple comparison 
correction and applying a significance threshold of FDR<0.05. In order to analyze the use of the different 
GRE elements we annotated our genes using annotations derived from the literature (Surjit et al., 2011) 
and gene lists derived from EnrichR website (generated from encode and Transfac annotation). We 
analysed the relative enrichment in GRE among those genes differentially expressed by Dex and Dex in 
the presence of TGF-b1 using a Fisher’s exact test. FunRich (v3.1.3), an open access standalone tool, 
was used to perform functional enrichment analysis. 
 
Data and Software Availability. All sequencing data are available from GEO under series number 
GSE104908   
 
Two-dimensional differential in gel electrophoresis (2D-DIGE). 2D-DIGE experiments were 
performed by using the minimal fluorescent labeling. Firstly, BEAS-2B cell lysates were harvested in 
solubilisation solution (7M urea, 2M thiourea, 4% CHAPS, 30mM Tris-HCl, pH8.5) containing 
phosphatase inhibitor cocktail (Sigma-Aldrich, P5726) and protease inhibitor cocktail (Sigma-Aldrich, 
P1860). Protein concentration was measured with Bradford protein assay (Bio-Rad, 500-0006). 
Secondly, minimal fluorescent labeling was conducted at a ratio of 400pmol CyDye (Cy3/Cy5, 
Lumiprobe) per 50µg protein. Simultaneously, an internal pooled standard consisting of equal aliquots 
from samples under comparison was labeled with Cy2. For each set of experiments, three or five gels 
were run for statistical analysis (t-test), and Cy3/Cy5 reverse labeling was performed to minimize 
potential dye labeling variability. Subsequently, the Immobiline DryStrips (7cm, pH3-10, BioRad) were 
rehydrated overnight with the combined labeled samples via passive loading. The isoelectric focusing 
was performed in an IPGphor Isoelectric focusing system (BioRad) according to the following schedule: 
(1) linear increase from 0 to 250V in 20min; (2) rapid increase from 250V to 4000V within 2h; (3) hold 
4000V for 3h. Strips were then submitted directly to the second-dimension electrophoresis. SDS-PAGE 
was performed using XCell SureLock Mini-Cell Electrophoresis System. IPG strips were denatured and 
reduced in the equilibration buffer (6M urea, 2% (w/v) SDS, 30% (v/v) glycerol, 50mM Tris-HCl, 65mM 
DTT, pH 8.8) for 15min, then alkylated in equilibration buffer with 135mM iodoacetamide for 15min. 
The IPG strips were loaded onto a Ready Gelâ IEF Precast Gels, which were run at the constant 
electromagnetic force 200V for approximately 40 minutes. Gels were scanned using the Typhoon-
Variable mode imager (GE healthcare) with 487, 532 and 635nm lasers for Cy2, Cy3 and Cy5, 
respectively. Image analysis was performed using DeCyder V7.0 software. Comparisons between all gels 
were conducted using an paired Student’s t-test analysis, which determined the variation between 
different treatments. Differential expressions of proteins present in the gels were deemed significant by 
a fold change of ≥ 1.2 and a p-value of  <0.05.  
 
Protein spots that displayed statistically significant differential expression were selected for 
identification by LC-MS/MS (liquid chromatography-tandem mass spectrometry). Fifty micro grams of 
TGF-β1-treated sample was taken from each of the biological replicates in the experimental series and 
pooled to form a preparative gel sample. The preparative gel was used for spot picking and later for 
protein identification by MS/MS. The preparative gel was then stained with Coomassie Blue G-250 for 
visualizing pick-up. A pick list containing the specific locations of proteins of interest on the gel was 
generated. The gel plugs consisting of the proteins of interest were manually excised from the preparative 
gel, then digested with modified porcine trypsin protease (Sigma-Aldrich, T6567) following the 
described protocol (Shevchenko et al., 2006). Samples were subjected to LC-MS/MS with 
an OrbiTRAP ELITE ETD mass spectrometer (Thermo Scientific). Briefly, 2µl containing tryptic 
peptides was applied to a C18 reversed-phase HPLC column (Dionex, 15cmx75µm) using a nanoUPLC 
system (Dionex, Ultimate 3000 RSLC). Bound peptides were eluted with a gradient mixture of solvent 
A (0.1% v/v formic acid) and solvent B (100% acetonitrile in 0.1% formic acid (v/v)) as follows: 3–12% 
B 1 min; 12–35% B 20 min; 35–80% B 2 min. Eluted peptides were analysed in Fourier transform mode 
(240,000 resolution) with mass range 300–1650 m/z, and the 20 most-intense peptide ions were 
automatically selected for MS/MS using collision-induced fragmentation in the linear ion trap. Peak lists 
were searched against the Uniprot human database using MASCOT (fixed 
modification: carbamidomethly Cys; variable modifications: oxidized Met, 
phosphorylated Ser/Thr/Tyr). Protein identifications were assigned on the basis of significance (p < 
0.01), concordance of observed and theoretical mass and pI from 2D gel positions, and with the 
requirement that at least two peptides were confidently assigned. 
 
Cell transfection. BEAS-2B cells were seeded at the density of 75,000 cells/well in 24-well plate in 
penicillin-streptomycin free medium overnight. Cells were co-transfected with pGRE-SEAP (Clontech 
Laboratories Inc., Mountain View, CA) and pGL3-Luc (Promega, Alexandria, NSW, Aus) plasmids 
using Lipofectamine® 2000 (Invitrogen, Carlsbad, CA). Transfected cells were pretreated with inhibitors 
30min prior to 40pM TGF-b1 for 24h or directly treated with TGF-b isoforms, and then incubated with 
30nM Dex for another 24h. Supernatants were collected for measurement of secreted human placental 
alkaline phosphatase (SEAP) following the instructions for chemiluminescence kit (Roche Applied 
Science, NSW, Aus). Luciferase expression was determined as transfection efficiency control as 
described. Pre-validated siRNAs (sequences shown as below) were transfected using Lipofectamine 
RNAiMAX (Invitrogen). 24h after transfection, cells were treated with 40pM TGF-b1 for 24h, and then 
incubated with 30nM Dex for further 4h after which total RNA was extracted to assess GC activity. 
 
Target siRNA ID Sequences 
CFL1 (Cofilin1) s2937 UUCAUGUCGUUGAACACCUTG 
CFL1 (Cofilin1) s2938 UGCAAUUCAUGCUUGAUCCCT 
LIMK1 s8188 UGUAUCGUGAGGGUCAUGCTC 
LIMK2 s8192 UCAAUGAUCACCUUGCAGCTC 
LIMK2 s8193 AAUGAUCUCACAGAGAACGAT 
SMAD3 s8401 UAGGGAUUCACGCAGACCUCG 
SMAD3 s8402 UUCGGGUCAACUGGUAGACAG 
PLD1 s10638 UUUCGAUAUAGAUAUAGUGCC 
PLD2 s10640 UUGCGAUAGAAAGACAUGGTC 
NCOR2 (SMRT) s18468 UCAGCUUAGAGAUCUGCUGCT 
NCOR2 (SMRT) s18469 UUGUUUCCGAGCGUGAUUCCT 
 
Western Blot Analysis. Western blotting was performed as described (Khau et al., 2011). Rabbit 
monoclonal anti-FKBP5 [EPR6617] (Abcam, ab126715) and mouse monoclonal anti-PLZF (D-9) (Santa 
cruz, sc-28319) were used to determine TGF-b1 impact on Dex-inducible proteins. Rabbit monoclonal 
anti-phospho-cofilin1 (Ser3) (Cell signaling, 3313) and mouse monoclonal anti-cofilin1 (Abcam, 
ab54532) were used to assess TGF-b1 induction on phospho-cofilin1. Rabbit monoclonal anti-SMRT 
(Cell signaling, 62370)  and rabbit monoclonal anti-Smad3 (Cell signaling, 9523) were used to assess 
SMRT and Smad3 level change. Anti-GAPDH (Abcam, ab37168) and anti-b-tubulin (Merck Millipore, 
MAB3408) were used as housekeeping proteins for loading control. Densitometry was performed using 
the image J program (1.48v, National Institute of Health, USA).  
 
RNA extraction and Quantitative Real Time PCR (qRT-PCR). Total RNA was extracted and real-
time PCR assays were performed using SYBR green reagents (BioRad). Primer sequences are listed as 
below. 
 
Genes Primer sequences (5’ to 3’) 
18srRNA# FP: CGCCGCTAGAGGTGAAATTC 
RP: TTGGCAAATGCTTTCGCTC 
GILZ# FP: TCCTGTCTGAGCCCTGAAGAG 
RP: AGCCACTTACACCGCAGAAC 
ENaCα# FP: AGCACAACCGCATGAAGAC 
RP: TGAGGTTGATGTTGAGGCTG 
PDK4# FP: CTTGGGAAAAGAAGACCTTAC 
RP: GTGCAGTGGAGTATGTATAAC 
PLZF# FP: GTTCCTGGATAGTTTGCG 
RP: CATGTCAGTGCCAGTATG 
PAI-1# FP: TCAGGCTGACTTCACGAGTCTTT 
RP: CTGCGCGACGTGGAGAG 
FKBP5# FP: AGATTGAGCTCCTTGATTTC 
RP: TGAATATCCCTCTCCTTTCC 
CDKN1C# FP: TCTGATCTCCGATTTCTTCG 
RP: CTCTTTGGGCTCTAAATTGG 
CFL-1* FP: CTATGATGCAACCTATGAGAC 
RP: CTGTCAGCTTCTTCTTGATG 
LIMK1* FP: GCTATCAAGGTGACACAC 
RP: ATGTACTCAGTGATGAAGTTG 
LIMK2* FP: CTTTCACCTCAGTCAGAAAAG 
RP: TATCAAGGTGACACACAAAG 
PLD1* FP: AAAAGATCTGGAGGACACAG 
RP: CCATCTTTTTGACCATCTGTAG 
PLD2* FP: AAGACTCATCCTCTAGGAAC 
RP: ATCTATGAGCAGATCTTCCG 
CYP27A1* FP: ATACGGATGCTTTCAATGAG 
RP: CGAACAGGATGTAGCAAATAG 
 
#    Primer sequences were obtained from the literature (Keenan et al., 2014; Salem et al., 2012) 
* KiCqStart pre-designed primers were purchased from Sigma-Aldrich 
 
Immunohistochemistry (IHC). Subjects used in this study were either nonasthmatic or asthmatics with 
varying asthma severities (classified by using Global initiative for Asthma guidelines) recruited from the 
Melbourne Epidemiological Study of Childhood Asthma (MESCA) cohort (all aged 42 years at the time 
of biopsy). The demographic data are provided in Table S5.  
Paraffin embedded sections of human airway (3µm) were stained with rabbit monoclonal antibodies to 
phospho-cofilin1 (Cell signaling, 3313), or IgG isotype control (Cell signaling, 3900) following the three 
layer immunoperoxidase staining protocol. Antibody staining was completed using the Dako EnVision 
anti-rabbit kit as appropriate (Dako, Carpinteria, CA), where sections were counterstained with 
hematoxylin. More detailed studies on the MESCA (Melbourne Epidemiological Study of Childhood 
Asthma)  cohort used in this study (Phelan et al., 2002) (Tai et al., 2014) and other IHC studies have 
been reported (Qiao et al., 2017; Ward et al., 2008).  
 
Staining for F-G actin. BEAS-2B cells were seeded onto 8-well chamber slides overnight, and then 
maintained in serum-free medium for 24h. After that, cells were pretreated with different inhibitors 
30min prior to 40pM TGF-b1 for further 24h. For F- and G-actin staining, cells were fixed in 10% (v/v) 
neutral buffered formalin (NBF) for 15min and permeabilized with 0.2% (v/v) Triton X-100 for 5min. 
After washing in PBS, cells were blocked with 0.1% Triton X-100 in 1% BSA/PBS solution for 15min, 
and then stained with Oregon-green 488 (green) phalloidin (1:50, Invitrogen Molecular Probes, O7466) 
and Alex-Fluor 594 (red) deoxyribonuclease1 (DNase1)-texas red conjugate (10mg/ml, Invitrogen 
Molecular Probes, D12372) for 20min at room temperature. Under these conditions, phalloidin and 
DNase1 bind F- and G-actin, respectively. Nuclei were stained with 4',6-diamidno-2-pheylindole (DAPI) 
(1:100 in PBS) for 10 min. Slides were mounted using DAKO fluorescent mounting media and examined 
using a Zeiss fluorescence microscope-live cell imaging system. 
 
Quantification of cytokines in supernatants by Enzyme-linked Immunosorbent Assay (ELISA).  
Supernatant were collected for measurement of cytokines like IL-8 (BD optEIATM, 555126), granulocyte 
macrophage colony-stimulating factor ((GM-CSF), BD optEIATM, 555244) by ELISA following the 
manufacturers’ instructions. 
 
Cell Viability. Cell viability was assessed using the Trypan blue exclusion method. Briefly, cells were 
initially inspected under the microscope for the presence of detached cells. Cell monolayers were then 
washed with 1mL PBS, and then harvested by the addition of trypsin prior to incubation with Trypan 
blue (0.25% (w/v) in 2% fetal bovine serum) for 5 minutes before counting stained and unstained cells. 
 
Statistical analyses. Data are presented as the mean ± SEM for n individual experiments. All data were 
statistically analyzed using GraphPad Prism 5.0 for Mac (Graphpad Software, San Diego, CA). One-way 
or two-way analyses of variance (ANOVA) with Bonferroni’s post hoc test were used to analyze the 
data. In some cases, paire two-tailed Student’s t test is used. A P value less than 0.05 was considered to 
be statistically significant.  
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